| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Impact Instrumentation is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cephalon is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BRI Biopharmaceutical Research Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Focus Health is a Kearney, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.